NHD Global
Cognitive & Neuropeptides · Source-reviewed dossier
Source-Reviewed Research Dossier
Semax is an ACTH(4-10)-derived heptapeptide analogue studied in ischemia, neuroprotection and gene-expression models. Recent public records remain predominantly preclinical and do not establish broad human cognitive or recovery claims.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2025 mouse study linked Semax with Oprm1-related deubiquitination and functional-recovery outcomes after spinal-cord injury.
The result is sex-, species- and injury-model-specific.
Read the primary studyA 2024 study reported partial compensation of ischemia-disrupted brain gene expression after ACTH-like peptide exposure.
Gene-expression normalization in rats is not a clinical outcome.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The result is sex-, species- and injury-model-specific.
View primary recordGene-expression normalization in rats is not a clinical outcome.
View primary recordThird-party publications selected for direct relevance.
Preclinical study. 2025. PMID 40692165.
Preclinical study. 2024. PMID 39767736.
Concise answers for researchers comparing identity, evidence and catalog variants.
Semax is an ACTH(4-10)-derived heptapeptide analogue studied in ischemia, neuroprotection and gene-expression models. Recent public records remain predominantly preclinical and do not establish broad human cognitive or recovery claims.
The accessible evidence is mainly animal and molecular research, with limited controlled human replication.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Recent Semax papers report molecular and functional findings in rats, female mice and cell models. They expand mechanism hypotheses but do not supply the…
Updated September 1, 2026
Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, also written ACTH(4–7)-Pro-Gly-Pro. It should not be confused with semaxanib, an unrelated small molecule with a similar name.
Updated September 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: XA10 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
